SCHEMBL3922980

SCHEMBL3922980

Cc1cc(Cl)c(O[C@H]2CCN(c3ccc(C[C@@H](C#N)C(=O)O)cn3)C2)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
REN P00797 6/20 0.46
HRH3 Q9Y5N1 1/20 0.39
ACACB O00763 13/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3919537 1.00 REN (0.46) RENHRH3ACACB
SCHEMBL3910660 1.00 REN (0.46) RENHRH3ACACB
SCHEMBL3921137 1.00 REN (0.46) RENHRH3ACACB
SCHEMBL4524107 1.00 REN (0.46) RENHRH3ACACB
SCHEMBL4528063 0.82 REN (0.65) REN
SCHEMBL4522708 0.82 REN (0.65) REN
SCHEMBL4516057 0.82 REN (0.65) REN
SCHEMBL4514433 0.82 REN (0.65) REN
SCHEMBL4514437 0.82 REN (0.65) REN
SCHEMBL4527678 0.81 REN (0.61) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088457-A1 Primary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS, LTD. (CH) 2009-04-02 US disclosed
EP-2029542-A2 PRIMARY AMINES AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2009-03-04 EP disclosed
WO-2007099509-A2 PRIMARY AMINES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088457-A1 Primary Amines as Renin Inhibitors REN, ACE, AGTR1 REN 1/4885HRH3 74/4885ACACB 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.